Talazoparib with or without enzalutamide for people with HRR-mutant mCRPC after abiraterone

A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate

This will see if adding enzalutamide to talazoparib, or using talazoparib alone, can slow cancer progression in people with HRR-mutant metastatic castration-resistant prostate cancer who have already taken abiraterone.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 126 (estimated)
• Ages: 18 Years and up
• Sex: Male
• Sponsor: Prostate Cancer Clinical Trials Consortium (Academic / other)
• Drugs / interventions: crizotinib, lapatinib, chemotherapy, prednisone
• Locations: 2 sites (Boston, Massachusetts and 1 other locations)
• Trial ID: NCT06844383 on ClinicalTrials.gov

What this trial studies

This randomized Phase 2 trial enrolls adults with metastatic castration-resistant prostate adenocarcinoma who have a pathogenic homologous recombination repair (HRR) mutation and prior treatment with abiraterone acetate. Participants are assigned to receive talazoparib alone or talazoparib combined with the androgen receptor signaling inhibitor enzalutamide, with oral dosing and scheduled clinic visits. Tumor tissue or circulating tumor DNA testing is used to confirm HRR mutations, and patients undergo regular imaging and PSA monitoring to track time to progression. Safety and efficacy endpoints will inform whether the combination provides added benefit over the PARP inhibitor alone in this biomarker-selected population.

Who should consider this trial

Good fit: Ideal candidates are adults with metastatic castration-resistant prostate adenocarcinoma who have a confirmed pathogenic HRR mutation, have previously received abiraterone acetate, can swallow oral medication, and can attend study visits and imaging.

Not a fit: Patients without HRR mutations, those with neuroendocrine differentiation or small cell features, or people who have not previously received abiraterone are unlikely to benefit from the studied comparison.

Why it matters

Potential benefit: If successful, the treatment strategy could delay disease progression and extend the time patients with HRR-mutant mCRPC remain on effective therapy.

How similar studies have performed: PARP inhibitors have shown meaningful benefit in HRR-mutant mCRPC in prior trials, but combining PARP inhibitors with androgen receptor inhibitors is still under active study with mixed early results.

Eligibility criteria

Inclusion Criteria

• Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.

NOTE: Privacy authorization may be either included in the informed consent or obtained separately.

* Participants ≥ 18 years of age.
* Are willing to be randomized into either study arm and adhere to the study protocol.
* Ability to swallow study capsules and/or tablets whole.
* Are willing to remain on study treatment and to continue undergoing study imaging despite PSA progression unless clinically deteriorating.
* Histological or cytological proof of adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
* Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes on tumor tissue or circulating tumor DNA testing: BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C. Assessment of HRR mutation status by germline or somatic testing. All testing must be per Clinical Laboratory Improvement Amendments (CLIA)-certified assay and may have occurred at any time prior to or at screening (not required to be completed within the screening window).
* Metastatic castration-resistant prostate cancer (mCRPC) as demonstrated by one of the following:

  * Metastatic disease documented by conventional imaging: computed tomography (CT)/magnetic resonance imaging (MRI) chest/abdomen/pelvis and bone scan are required to be performed, but metastases do not need to be seen on both modalities. Measurable disease is not required.
  * Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease with negative conventional imaging. PSMA PET imaging is not required to be performed, but may be used to document metastases when relevant.
* Received prior abiraterone acetate with prednisone for mHSPC or locally advanced disease and on which progressed via a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination or radiographic progression by any form of imaging.
* Progressive disease at start of treatment and in the setting of medical or surgical castration as defined by 1 or more of the following 4 criteria:

  * PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval. If PSA rise is the only indication of progression at start of study treatment, a minimum PSA of 1.0 ng/mL is required and all measured PSA values have to be considered to make a determination of progression.
  * Soft tissue disease progression as defined by RECIST 1.1.
  * Bone disease progression defined by PCWG3 with 2 or more new metastatic bone lesions on a whole-body radionuclide bone scan.
  * Appearance of newly identified, convincingly positive lesions consistent with metastatic prostate cancer on PSMA PET.
* Surgically or medically castrated, with testosterone levels of \<50 ng/dL. If the participant is medically castrated, continuous dosing with a gonadotropin-releasing hormone agonist or antagonist must be demonstrated by testosterone level of \<50 ng/dL and planned to continue throughout study participation.
* Eastern Cooperative Oncology Group (ECOG) status of ≤1 (Appendix A: Performance Status Criteria).
* Normal organ function with acceptable initial laboratory values within 14 days of treatment start:

  * Absolute neutrophil count ≥ 1,500/µl
  * Hemoglobin ≥ 9g/dl
  * Platelet count ≥ 100,000/µl
  * Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)
  * Potassium ≥ 3.5 mmol/L (within institutional normal range)
  * Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease)
  * Serum glutamic oxaloacetic transaminase/aspartate transaminase (AST) ≤ 2.5 x ULN
  * Serum glutamic pyruvic transaminase/ alanine transaminase (ALT) ≤ 2.5 x ULN
* Participants must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 4 months after the last dose of study drug. Sperm donation is prohibited during the study and for 4 months after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.

Exclusion Criteria

* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer.
* Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks. Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.
* Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed \>6 months prior to start of study treatment.
* Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.
* Prior treatment with a PARP inhibitor.
* Concurrent treatment with crizotinib.
* Prior platinum-based chemotherapy for the treatment of prostate cancer.
* Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.
* Current use of strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) and inducers (e.g., rifampin), strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine and St. John's Wort), moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil and nafcillin), or substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin), or CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index unless considered medically necessary to treat a life-threatening condition.
* Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization are not eligible.
* Use of hormonal agents with anti-tumor activity against prostate cancer including 5-alpha reductase inhibitors, androgens (e.g., testosterone), cytoproterone acetate, progestational agents, and estrogens/diethylstilbestrol within 28 days prior to the start of study treatment.
* Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC-HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation or plans to initiate treatment with these products/alternative therapies during the entire duration of the study.
* Participants receiving a blood transfusion within 14 days of randomization are not eligible.
* History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization.
* Medical conditions such as uncontrolled hypertension as indicated by a resting systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 90 mm Hg at screening, uncontrolled diabetes mellitus, and cardiac disease that would preclude participation, as determined by the investigator.
* Untreated known or suspected brain metastases or spinal cord compression or clinically significant malignant epidural disease.
* Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.
* Grade \>2 treatment-related toxicity from prior therapy except alopecia or peripheral neuropathy.
* Known allergy to any of the compounds under investigation.
* Any other condition which, in the opinion of the Investigator, would preclude participation in this trial.

Where this trial is running

Boston, Massachusetts and 1 other locations

• Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)

Study contacts

• Principal investigator: Alicia Morgans, MD — Dana-Farber Cancer Institute
• Study coordinator: Sarah Wise

Conditions Prostate Cancer; mCRPC; talazoparib; enzalutamide; PARP inhibitor; TALENT; androgen receptor signaling inhibitor; Prostate Cancer Clinical Trials Consortium, LLC